SG11201406468YA - Salt form of a human hi stone methyltransf erase ezh2 inhibitor - Google Patents
Salt form of a human hi stone methyltransf erase ezh2 inhibitorInfo
- Publication number
- SG11201406468YA SG11201406468YA SG11201406468YA SG11201406468YA SG11201406468YA SG 11201406468Y A SG11201406468Y A SG 11201406468YA SG 11201406468Y A SG11201406468Y A SG 11201406468YA SG 11201406468Y A SG11201406468Y A SG 11201406468YA SG 11201406468Y A SG11201406468Y A SG 11201406468YA
- Authority
- SG
- Singapore
- Prior art keywords
- eisai
- international
- andover
- drive
- corporate
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000003839 salts Chemical group 0.000 title abstract 2
- 239000004575 stone Substances 0.000 title abstract 2
- 101150090105 Ezh2 gene Proteins 0.000 title 1
- 102000016397 Methyltransferase Human genes 0.000 title 1
- 108060004795 Methyltransferase Proteins 0.000 title 1
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 abstract 1
- 239000004305 biphenyl Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- -1 tetrahydro-2H-pyran-4- O Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261624215P | 2012-04-13 | 2012-04-13 | |
| PCT/US2013/036193 WO2013155317A1 (en) | 2012-04-13 | 2013-04-11 | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201406468YA true SG11201406468YA (en) | 2015-01-29 |
Family
ID=49328166
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201406468YA SG11201406468YA (en) | 2012-04-13 | 2013-04-11 | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
| SG10201608577RA SG10201608577RA (en) | 2012-04-13 | 2013-04-11 | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
| SG10201912109QA SG10201912109QA (en) | 2012-04-13 | 2013-04-11 | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201608577RA SG10201608577RA (en) | 2012-04-13 | 2013-04-11 | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
| SG10201912109QA SG10201912109QA (en) | 2012-04-13 | 2013-04-11 | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
Country Status (26)
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| WO2013075084A1 (en) | 2011-11-18 | 2013-05-23 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| CA2862289C (en) | 2012-02-10 | 2019-11-26 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| IL308807B2 (en) | 2012-04-13 | 2025-08-01 | Epizyme Inc | Combination therapy for treating cancer |
| PL2836491T3 (pl) * | 2012-04-13 | 2017-08-31 | Epizyme, Inc. | Postać soli inhibitora ludzkiej metylotransferazy histonowej EZH2 |
| US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| IL308613A (en) * | 2012-10-15 | 2024-01-01 | Epizyme Inc | Cancer treatment methods |
| US9006242B2 (en) * | 2012-10-15 | 2015-04-14 | Epizyme, Inc. | Substituted benzene compounds |
| US9745305B2 (en) | 2013-03-15 | 2017-08-29 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| EA030196B1 (ru) | 2013-04-30 | 2018-07-31 | Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед | Ингибиторы энхансера zeste гомолога 2 |
| US9556157B2 (en) | 2013-07-10 | 2017-01-31 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| EP3033334A1 (en) | 2013-08-15 | 2016-06-22 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| EA038869B1 (ru) | 2013-10-16 | 2021-10-29 | Эпизим, Инк. | Кристаллические формы гидрохлорида n-((4,6-диметил-2-оксо-1,2-дигидропиридин-3-ил)метил)-5-(этил(тетрагидро-2h-пиран-4-ил)амино)-4-метил-4'-(морфолинометил)-[1,1'-бифенил]-3-карбоксамида, фармацевтические композиции на их основе и способы их применения |
| US20160228447A1 (en) * | 2013-10-18 | 2016-08-11 | Epizyme, Inc. | Method of treating cancer |
| US9738630B2 (en) | 2013-11-19 | 2017-08-22 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
| CN116019921A (zh) | 2013-12-06 | 2023-04-28 | Epizyme股份有限公司 | 用于治疗癌症的组合疗法 |
| LT3157527T (lt) | 2014-06-17 | 2023-07-25 | Epizyme, Inc. | Ezh2 inhibitoriai, skirti limfomos gydymui |
| CN106687463B (zh) | 2014-06-20 | 2019-04-09 | 星座制药公司 | 一种乙酰胺类化合物的晶型 |
| CA2963149A1 (en) | 2014-10-16 | 2016-04-21 | Epizyme, Inc. | Method for treating cancer |
| MX383484B (es) | 2014-11-17 | 2025-03-11 | Epizyme Inc | Método para tratar el cáncer. |
| AR102767A1 (es) | 2014-12-05 | 2017-03-22 | Lilly Co Eli | Inhibidores de ezh2 |
| SG10201902664RA (en) | 2015-04-20 | 2019-04-29 | Epizyme Inc | Combination therapy for treating cancer |
| MX387885B (es) | 2015-06-10 | 2025-03-19 | Epizyme Inc | Inhibidores de ezh2 para tratar linfomas. |
| WO2017035234A1 (en) | 2015-08-24 | 2017-03-02 | Epizyme, Inc. | Method for treating cancer |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| WO2017040190A1 (en) | 2015-08-28 | 2017-03-09 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide |
| JP2019503391A (ja) | 2016-01-29 | 2019-02-07 | エピザイム，インコーポレイティド | 癌を処置するための併用療法 |
| WO2017210395A1 (en) * | 2016-06-01 | 2017-12-07 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
| EP3471830A4 (en) | 2016-06-17 | 2020-02-26 | Epizyme Inc | EZH2 INHIBITORS TO TREAT CANCER |
| US10457640B2 (en) | 2016-10-19 | 2019-10-29 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of EZH2 |
| US11214561B2 (en) * | 2017-01-25 | 2022-01-04 | Ancureall Pharmaceutical (Shanghai) Co., Ltd. | Histone methyltransferase EZH2 inhibitor, preparation method and pharmaceutical use thereof |
| WO2018183885A1 (en) | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Combination therapy for treating cancer |
| US11602529B2 (en) | 2017-06-02 | 2023-03-14 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| CN111093660A (zh) | 2017-09-05 | 2020-05-01 | Epizyme股份有限公司 | 用于治疗癌症的组合疗法 |
| EP3823671B1 (en) | 2018-07-09 | 2024-02-07 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
| EP4003532B1 (en) | 2019-07-24 | 2024-09-04 | Constellation Pharmaceuticals, Inc. | Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide |
| JP2022545467A (ja) | 2019-08-22 | 2022-10-27 | ジュノー セラピューティクス インコーポレイテッド | Ｔ細胞療法とｚｅｓｔｅホモログ２エンハンサー（ＥＺＨ２）阻害剤との併用療法および関連方法 |
| EP4077314A1 (en) * | 2019-12-20 | 2022-10-26 | Epizyme, Inc. | Crystalline hydrobromide salt of a ezh2 inhibitor, its preparation and pharmaceutical composition useful for the treatment of cancer |
| WO2022208552A1 (en) * | 2021-03-31 | 2022-10-06 | Msn Laboratories Private Limited, R&D Center | Crystalline forms of [1,1'-Biphenyl]-3-carboxamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)-, hydrobromide (1:1) and process for its preparation thereof |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0733729A (ja) | 1993-07-26 | 1995-02-03 | Kirin Brewery Co Ltd | Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法 |
| RU2128644C1 (ru) | 1993-12-27 | 1999-04-10 | Эйсай Ко., Лтд. | Производные антраниловой кислоты или их фармакологически приемлемые соли, промежуточные продукты для их получения и лекарственный препарат на их основе |
| DE19516776A1 (de) | 1995-05-10 | 1996-11-14 | Boehringer Ingelheim Int | Chromatin-Regulatorgene |
| US5741819A (en) | 1995-06-07 | 1998-04-21 | 3-Dimensional Pharmaceuticals, Inc. | Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors |
| JP3906935B2 (ja) | 1995-12-18 | 2007-04-18 | 杏林製薬株式会社 | Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
| BR9914207A (pt) | 1998-09-30 | 2001-07-03 | Procter & Gamble | Ceto-amidas 2-substituìdas |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
| DK1357111T3 (da) | 2000-12-28 | 2009-11-02 | Shionogi & Co | 2-pyridonderivater med affinitet for cannabinoid type 2-receptor |
| US7700293B2 (en) | 2001-08-02 | 2010-04-20 | The Regents Of The University Of Michigan | Expression profile of prostate cancer |
| TW200303304A (en) * | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
| US20050101590A1 (en) | 2002-02-19 | 2005-05-12 | Kiyoshi Yasui | Antipruritics |
| TW200306155A (en) | 2002-03-19 | 2003-11-16 | Du Pont | Benzamides and advantageous compositions thereof for use as fungicides |
| US7442685B2 (en) | 2003-06-13 | 2008-10-28 | The University Of North Carolina At Chapel Hill | DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia |
| MXPA06010520A (es) | 2004-03-30 | 2007-03-26 | Chiron Corp | Derivados de tiofeno sustituidos como agentes anticancerosos. |
| WO2005118796A2 (en) | 2004-06-01 | 2005-12-15 | The University Of North Carolina At Chapel Hill | Reconstituted histone methyltransferase complex and methods of identifying modulators thereof |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| US7923219B2 (en) | 2005-06-02 | 2011-04-12 | The University Of North Carolina At Chapel Hill | Ubiquitin E3 ligase |
| FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| EP1940821B1 (de) | 2005-10-19 | 2013-03-20 | Grünenthal GmbH | Neue vanilloid-rezeptor liganden und ihre verwendung zur herstellung von arzneimitteln |
| WO2007050347A1 (en) | 2005-10-21 | 2007-05-03 | Merck & Co., Inc. | Potassium channel inhibitors |
| EP1941060B1 (en) | 2005-10-28 | 2012-02-29 | The University of North Carolina At Chapel Hill | Protein demethylases comprising a jmjc domain |
| WO2007070818A1 (en) | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| WO2007087015A1 (en) | 2006-01-20 | 2007-08-02 | The University Of North Carolina At Chapel Hill | Diagnostic and therapeutic targets for leukemia |
| CN101443007A (zh) | 2006-05-15 | 2009-05-27 | Irm责任有限公司 | Terephthalamate化合物和组合物及其作为hiv整合酶抑制剂的用途 |
| CA2652634A1 (en) | 2006-05-18 | 2007-11-29 | Amphora Discovery Corporation | Certain substituted quinolones, compositions, and uses thereof |
| EP2086318A4 (en) | 2006-10-10 | 2009-12-23 | Burnham Inst Medical Research | NEUROPROTECTIVE COMPOSITIONS AND CORRESPONDING METHODS |
| MX2009008531A (es) | 2007-02-16 | 2009-08-26 | Amgen Inc | Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met. |
| US8338437B2 (en) | 2007-02-28 | 2012-12-25 | Methylgene Inc. | Amines as small molecule inhibitors |
| WO2008113006A1 (en) | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
| DE102007017884A1 (de) | 2007-04-13 | 2008-10-16 | Grünethal GmbH | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
| US20090012031A1 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | EZH2 Cancer Markers |
| DE102007047737A1 (de) * | 2007-10-05 | 2009-04-30 | Merck Patent Gmbh | Piperidin- und Piperazinderivate |
| US8247401B2 (en) | 2007-10-31 | 2012-08-21 | Merck Sharp & Dohme Corp. | P2X3 receptor antagonists for treatment of pain |
| NZ586418A (en) | 2007-12-19 | 2012-09-28 | Cancer Rec Tech Ltd | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
| WO2009124137A2 (en) | 2008-04-01 | 2009-10-08 | Mount Sinai School Of Medicine Of New York University | Method of suppressing gene transcription through histone lysine methylation |
| US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| WO2010017355A2 (en) | 2008-08-08 | 2010-02-11 | New York Blood Center | Small molecule inhibitors of retroviral assembly and maturation |
| FR2934995B1 (fr) | 2008-08-14 | 2010-08-27 | Sanofi Aventis | Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique |
| US20120065247A1 (en) | 2009-03-27 | 2012-03-15 | Discoverybiomed, Inc. | Modulating ires-mediated translation |
| US20110021362A1 (en) | 2009-07-20 | 2011-01-27 | Constellation Pharmaceuticals | Agents for stimulating activity of methyl modifying enzymes and methods of use thereof |
| US8329149B2 (en) | 2009-12-30 | 2012-12-11 | Avon Products, Inc. | Topical lightening composition and uses thereof |
| EP2566328B1 (en) * | 2010-05-07 | 2015-03-04 | GlaxoSmithKline LLC | Indazoles |
| JP5889875B2 (ja) * | 2010-05-07 | 2016-03-22 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | アザインダゾール |
| CN102970869B (zh) * | 2010-05-07 | 2014-07-16 | 葛兰素史密斯克莱有限责任公司 | 吲哚 |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| BR112013005806B1 (pt) | 2010-09-10 | 2022-05-10 | Epizyme, Inc | Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2 |
| WO2012068589A2 (en) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2012075080A1 (en) | 2010-12-01 | 2012-06-07 | Glaxosmithkline Llc | Indoles |
| EP2646454B1 (en) | 2010-12-03 | 2015-07-08 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| JP6321619B2 (ja) | 2012-03-12 | 2018-05-09 | エピザイム インコーポレイテッド | ヒトｅｚｈ２の阻害剤およびその使用方法 |
| PL2836491T3 (pl) | 2012-04-13 | 2017-08-31 | Epizyme, Inc. | Postać soli inhibitora ludzkiej metylotransferazy histonowej EZH2 |
| IL308807B2 (en) | 2012-04-13 | 2025-08-01 | Epizyme Inc | Combination therapy for treating cancer |
| US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| IL308613A (en) | 2012-10-15 | 2024-01-01 | Epizyme Inc | Cancer treatment methods |
| EA038869B1 (ru) | 2013-10-16 | 2021-10-29 | Эпизим, Инк. | Кристаллические формы гидрохлорида n-((4,6-диметил-2-оксо-1,2-дигидропиридин-3-ил)метил)-5-(этил(тетрагидро-2h-пиран-4-ил)амино)-4-метил-4'-(морфолинометил)-[1,1'-бифенил]-3-карбоксамида, фармацевтические композиции на их основе и способы их применения |
-
2013
- 2013-04-11 PL PL13774979T patent/PL2836491T3/pl unknown
- 2013-04-11 EP EP16191716.6A patent/EP3184523B1/en active Active
- 2013-04-11 RU RU2014145544A patent/RU2658911C2/ru not_active Application Discontinuation
- 2013-04-11 RS RSP20191175 patent/RS59392B1/sr unknown
- 2013-04-11 IN IN9068DEN2014 patent/IN2014DN09068A/en unknown
- 2013-04-11 RS RS20170198A patent/RS55690B1/sr unknown
- 2013-04-11 BR BR112014025508-3A patent/BR112014025508B1/pt active IP Right Grant
- 2013-04-11 KR KR1020247041285A patent/KR20250005505A/ko active Pending
- 2013-04-11 EP EP19180479.8A patent/EP3628670B1/en active Active
- 2013-04-11 ES ES16191716T patent/ES2745016T3/es active Active
- 2013-04-11 JP JP2015505912A patent/JP6255382B2/ja active Active
- 2013-04-11 DK DK19180479.8T patent/DK3628670T3/da active
- 2013-04-11 HU HUE19180479A patent/HUE060881T2/hu unknown
- 2013-04-11 SG SG11201406468YA patent/SG11201406468YA/en unknown
- 2013-04-11 CN CN201810245662.3A patent/CN108358899B/zh active Active
- 2013-04-11 KR KR1020207015664A patent/KR102438340B1/ko active Active
- 2013-04-11 HU HUE16191716A patent/HUE045353T2/hu unknown
- 2013-04-11 EP EP22200677.7A patent/EP4190777A1/en active Pending
- 2013-04-11 MX MX2014012380A patent/MX362339B/es active IP Right Grant
- 2013-04-11 HR HRP20170295TT patent/HRP20170295T1/hr unknown
- 2013-04-11 KR KR1020227029511A patent/KR102744039B1/ko active Active
- 2013-04-11 SM SM20170132T patent/SMT201700132T1/it unknown
- 2013-04-11 KR KR1020147030684A patent/KR102120883B1/ko active Active
- 2013-04-11 CN CN201380030902.3A patent/CN104603130B/zh active Active
- 2013-04-11 SI SI201330551A patent/SI2836491T1/sl unknown
- 2013-04-11 LT LTEP16191716.6T patent/LT3184523T/lt unknown
- 2013-04-11 PL PL19180479.8T patent/PL3628670T3/pl unknown
- 2013-04-11 DK DK16191716.6T patent/DK3184523T3/da active
- 2013-04-11 LT LTEP13774979.2T patent/LT2836491T/lt unknown
- 2013-04-11 PT PT16191716T patent/PT3184523T/pt unknown
- 2013-04-11 WO PCT/US2013/036193 patent/WO2013155317A1/en not_active Ceased
- 2013-04-11 PL PL16191716T patent/PL3184523T3/pl unknown
- 2013-04-11 HU HUE13774979A patent/HUE031976T2/en unknown
- 2013-04-11 SI SI201331566T patent/SI3184523T1/sl unknown
- 2013-04-11 DK DK13774979.2T patent/DK2836491T3/en active
- 2013-04-11 PT PT137749792T patent/PT2836491T/pt unknown
- 2013-04-11 NZ NZ700761A patent/NZ700761A/en unknown
- 2013-04-11 ES ES19180479T patent/ES2931316T3/es active Active
- 2013-04-11 SG SG10201608577RA patent/SG10201608577RA/en unknown
- 2013-04-11 SG SG10201912109QA patent/SG10201912109QA/en unknown
- 2013-04-11 IL IL296199A patent/IL296199B2/en unknown
- 2013-04-11 PT PT191804798T patent/PT3628670T/pt unknown
- 2013-04-11 SM SM20190501T patent/SMT201900501T1/it unknown
- 2013-04-11 IL IL282732A patent/IL282732B2/en unknown
- 2013-04-11 MX MX2019000449A patent/MX384641B/es unknown
- 2013-04-11 US US14/394,431 patent/US9394283B2/en active Active
- 2013-04-11 AU AU2013245878A patent/AU2013245878B2/en active Active
- 2013-04-11 CA CA2870005A patent/CA2870005C/en active Active
- 2013-04-11 EP EP13774979.2A patent/EP2836491B1/en active Active
- 2013-04-11 ES ES13774979.2T patent/ES2617379T3/es active Active
-
2014
- 2014-10-07 IL IL235045A patent/IL235045B/en active IP Right Grant
-
2016
- 2016-06-30 US US15/199,522 patent/US9872862B2/en active Active
-
2017
- 2017-03-06 CY CY20171100290T patent/CY1119383T1/el unknown
- 2017-10-12 JP JP2017198642A patent/JP6634058B2/ja active Active
- 2017-12-11 US US15/837,390 patent/US10245269B2/en active Active
-
2018
- 2018-01-09 AU AU2018200168A patent/AU2018200168B2/en active Active
- 2018-10-02 JP JP2018187463A patent/JP2018199740A/ja active Pending
-
2019
- 2019-02-08 US US16/270,752 patent/US10821113B2/en active Active
- 2019-04-21 IL IL266165A patent/IL266165B/en active IP Right Grant
- 2019-09-13 HR HRP20191653TT patent/HRP20191653T1/hr unknown
- 2019-09-18 CY CY20191100981T patent/CY1122883T1/el unknown
-
2020
- 2020-09-25 US US17/032,432 patent/US11491163B2/en active Active
-
2022
- 2022-09-29 US US17/936,555 patent/US12251386B2/en active Active
-
2025
- 2025-02-13 US US19/053,007 patent/US20250268905A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201406468YA (en) | Salt form of a human hi stone methyltransf erase ezh2 inhibitor | |
| SG11201403216UA (en) | Methods and compounds useful in the synthesis of orexin-2 receptor antagonists | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201909278SA (en) | Fungicidal oxadiazoles | |
| SG11201909376TA (en) | Crystalline forms of a jak inhibitor compound | |
| SG11201901197PA (en) | Amino-pyrrolopyrimidinone compounds and methods of use thereof | |
| SG11201907846VA (en) | Therapeutic rna | |
| SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
| SG11201809714TA (en) | Piperidines as menin inhibitors | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201804134YA (en) | Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment | |
| SG11201810268YA (en) | Combination therapy with notch and pd-1 or pd-l1 inhibitors | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201808878UA (en) | Heterocyclic compounds as ret kinase inhibitors | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201804647TA (en) | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201901251SA (en) | Aminopyrimidines as alk inhibitors | |
| SG11201408271VA (en) | Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases | |
| SG11201407474VA (en) | An audio signal output device and method of processing an audio signal |